This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F13%3A00065660%21RIV14-MZ0-14110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F13%3A00065660%21RIV14-MZ0-14110___
rdf:type
skos:Concept n11:Vysledek
dcterms:description
In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide).
dcterms:title
Salvage lenalidomide in four rare oncological diseases Salvage lenalidomide in four rare oncological diseases
skos:prefLabel
Salvage lenalidomide in four rare oncological diseases Salvage lenalidomide in four rare oncological diseases
skos:notation
RIV/00216224:14110/13:00065660!RIV14-MZ0-14110___
n11:predkladatel
n12:orjk%3A14110
n3:aktivita
n4:P n4:I
n3:aktivity
I, P(NT12215), P(NT13190)
n3:cisloPeriodika
5
n3:dodaniDat
n18:2014
n3:domaciTvurceVysledku
n5:7227086 n5:4376285 n5:7806132 n5:9685596
n3:druhVysledku
n8:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
103921
n3:idVysledku
RIV/00216224:14110/13:00065660
n3:jazykVysledku
n20:eng
n3:klicovaSlova
Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease
n3:klicoveSlovo
n9:Castleman%20disease n9:Langerhans%20cell%20histiocytosis n9:angiomatosis n9:Erdheim-Chester%20disease
n3:kodStatuVydavatele
IT - Italská republika
n3:kontrolniKodProRIV
[3A458B6AC2C6]
n3:nazevZdroje
Tumori
n3:obor
n19:FD
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
8
n3:projekt
n6:NT12215 n6:NT13190
n3:rokUplatneniVysledku
n18:2013
n3:svazekPeriodika
99
n3:tvurceVysledku
Krejčí, Marta Szturz, Petr Mayer, Jiří Rehak, Zdenek Adam, Zdeněk Koukalova, Renata Moulis, Mojmír Křen, Leoš
s:issn
0300-8916
s:numberOfPages
6
n17:doi
10.1700/1377.15326
n14:organizacniJednotka
14110